详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

122| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Sumitomo Pharma Oncology, Inc. [2]Tongji Hospital Wuhan, China, 430030 [3]Sir Run Run Shaw Hospital School of Medicine, Zhejiang University Hangzhou, Zhejiang, China, 310016 [4]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310022 [5]Xin Jiang Tumor Hospital, Xin Jiang Medical University Urumqi, Xinjiang, China, 830000 [6]Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin, China, 300202 [7]West China Hospital, Sichuan University Chengdu, Sichuan, China, 610041 [8]Zhongshan Hospital Shanghai, Shanghai, China, 200032 [9]Fudan University Shanghai Cancer Center Shanghai, Shanghai, China, 200032 [10]General Hospital of Ningxia Medical University Yinchuan, Ningxia, China, 750004 [11]The First Hospital of China Medical University Shenyang, Liaoning, China, 110002 [12]The First Bethune Hospital of Jilin University Changchun, Jilin, China, 130021 [13]Jilin Cancer Hospital Jilin, Jilin, China, 130021 [14]The 81 Hospital of the Chinese People's Liberation Army Nanjing, Jiangsu, China, 210002 [15]Jiang Su Cancer Hospital Nanjing, Jiangsu, China, 210009 [16]Jiangsu Province Hospital Nanjing, Jiangsu, China, 210029 [17]Hunan Cancer Hospital Changsha, Hunan, China, 410006 [18]The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China, 450003 [19]Henan Cancer Hospital Zhengzhou, Henan, China, 450008 [20]Harbin Medical University Cancer Hospital Heilongjiang, Heilongjiang, China, 150081 [21]Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China, 510060 [22]Southern Medical University, Nanfang Hospital Guangzhou, Guangdong, China, 510515 [23]Fujian Medical University Union Hospital Fuzhou, Fujian, China, 350001 [24]Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021

研究目的：

The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.